Liver transplant: myths and realities James Trotter, MD Baylor University Medical Center Dallas, Texas.

Slides:



Advertisements
Similar presentations
Ken Andreoni, MD Chair UNOS Kidney Comm The Ohio State University
Advertisements

CURRENT STATE OF LIVER ALLOCATION AND DISTRIBUTION John R. Lake, MD University of Minnesota Medical School.
UNOS Region 8 MELD29 Trial Analysis of the Results
SRTR Transplant Benefit-Based Liver Allocation Robert M. Merion, MD, FACS OPTN/UNOS Liver Forum Atlanta, GA April 12, 2010.
Basics of Organ Transplantation Lon Eskind, MD Director Liver Transplant, CMC Assoc. Medical Director of LifeShare.
Concentric Circle Liver Distribution Models
Risё Stribling, MD Medical Director of Liver Transplant St Luke’s Medical Center Associate Professor of Surgery Baylor College of Medicine.
Scandiatransplant Waiting List Denmark James Heaf.
Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.
OPTN Session 3 OPTN Policy Development and Feedback from RFI / Highlights of concepts being explored April 12, 2010.
Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients Deirdre Sawinski MD, Kimberly A.
Heart Transplantation in the United States OPTN-SRTR Report Heart-Lung With slight fluctuations over the last few years, the number of patients.
Liver and Intestinal Organ Transplantation Committee Spring 2014 Update.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.
Tackling geographic disparity – Redistribution of livers Ryutaro Hirose, MD Professor, Surgery Vice Chair, UNOS Liver Intestine committee Region 5 Collaborative.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
Liver Transplant Data for Regional Meetings Spring 2015.
The Recipient Experience Jaime Myers, RN, MSN, CCTC April 29, 2011.
Liver Cirrhosis S. Diana Garcia
An International Case Study of Lung Transplantation
Cholestatic liver diseases:
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
+ Liver Transplantation for PSC Patients A Transplant Surgeon’s Perspective Tiffany Anthony, MD Annette C. and Harold C. Simmons Transplant Institute Baylor.
Living Donor Liver Transplantation in PSC Patients Giuliano Testa, MD, FACS, MBA Surgical Director, Living Donor Liver Transplantation Baylor University.
Proposal to Delay the HCC Exception Score Assignment (Resolution 9) Liver and Intestine Committee David Mulligan, Chair November 12 and 13, 2014.
MELD and UNOS James Trotter, MD Baylor University Medical Center Dallas, Texas.
OPTN Differences in the Opportunity for Transplantation within the US Co-chairs: S. McDiarmid MD and K. Olthoff MD Working Group 4: “Improve the Efficiency,
 Exemplary Care  Cutting-edge Research  World-class Education  Raghavan Murugan MD, MS, FRCP Associate Professor Dept. of Critical Care Medicine Clinical.
The Expanded Criteria Donors in Kidney Transplantation: 3 Years Experience FAM Shaheen, B. Al-Attar, MZ Souqiyyeh, J.E Cillo, A. Al Sayyari.
Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to within Milan Criteria before Liver Transplantation Neil Mehta, MD; Jennifer Guy,
5-Azacitidine For Myelodysplasia Before Allogeneic Hematopoietic Cell Transplantation Field T et al. Bone Marrow Transplant 2009:[Epub ahead of print].
Liver and Intestinal Organ Transplantation Committee Update Report David Mulligan, MD, Chair OPTN/UNOS Board of Directors Meeting November 12-13, 2014.
Implementing pre-transplant performance review by the Membership and Professional Standards Committee Membership & Professional Standards Committee Fall.
Andreas A. Rostved, MD Research assistant Department of Surgical Gastroenterology and Transplantation Rigshospitalet – Copenhagen University Hospital Denmark.
Level 6 Discharges from Bradford Teaching Hospitals: Destination and Survival Dr Kath Lambert SpR in Palliative Medicine BRI.
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
A2ALL When Using A2ALL Slides We welcome the use of A2ALL slides, as we value the distribution of our research for the benefit of patient care and transplant.
Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.
United States Organ Transplantation SRTR & OPTN Annual Data Report, 2011 Kidney.
소화기내과 김경엽 Gastroenterology 2011;140:
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
Liver Transplantation in PSC: What to Know and Recent Updates Brett E. Fortune, MD, MSc Assistant Professor of Medicine and Surgery Yale School of Medicine.
Cadaveric vs Living Donation; Comparing Options
Acute Liver Failure Anand Annamalai.
Optimal Timing of Hepatitis C Treatment for Patients on the Liver Transplant Waiting List Jagpreet Chhatwal, PhD,1,2 Sumeyye Samur, PhD1,2 Brian Kues,
MELD Score, Listing for Liver Transplant, and Organ Allocation
Living Donor Transplants
Liver Transplant Data for Regional Meetings
Liver transplantation and PSC
HCV & liver transplantation
Nalaka Gunawansa, John McCall, Stephen Munn, Peter Johnston
Copyright © 2006 American Medical Association. All rights reserved.
Liver Transplantation: 50 years
Outline.
Primary Sclerosing Cholangitis in Children
Basics of PSC Christopher L. Bowlus, MD
Liver Transplant For Patients with PSC
Changes to HCC Criteria for Auto Approval
Living donor liver transplantation: is the hype over?
Recent Advances in Liver Transplantation
Risk Factors associated with Outcome
Alcoholic liver disease in intensive care
Volume 155, Issue 5, Pages e3 (November 2018)
Proposal to Delay the HCC Exception Score Assignment
Proposal to Delay the HCC Exception Score Assignment
Liver Transplant Data for Regional Meetings
Proposal to Cap the HCC Exception Score at 34
Volume 156, Issue 5, Pages e3 (April 2019)
Kantarjian HM et al. Blood 2008;112:Abstract 635.
(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.
Presentation transcript:

Liver transplant: myths and realities James Trotter, MD Baylor University Medical Center Dallas, Texas

1. The liver transplant candidates who are the sickest get transplanted first. Myth

1. The need for liver transplant is only judged by MELD score (waiting list mortality). Reality

MELD score 10(0.957ln(Cr) ln(bilirubin) ln(INR) ) Wiesner et al. Gastro, 2003

Transplant indication: LDLT vs. DDLT % PSC is a common indication for LDLT

2.The outcome for an individual liver recipient can be accurately predicted. Myth

2.When all known variables are accounted, the ability to predict outcome for an individual patient is about 60 %. Reality

3.All liver transplant programs have similar outcomes. Myth

3.The outcome after liver transplant varies widely between centers. Reality

4.Liver transplant is a therapy that effectively cures PSC. Myth

4.Liver transplant is an effective therapy for PSC, but a.you trade one set of pre-transplant problems for a different set of post-transplant problems b. PSC can recur Reality

Five-year patient survival Charlton, Gastro, 2011

130 patients transplanted with PSC in Denver male 77 % inflammatory bowel disease 71 % median age (at transplant)46 y (range 18 – 71) What will happen afterwards?

130 patients transplanted with PSC in Denver overall survival 82 % overall PSC recurrence-free survival 67 % live donor recipient 15 % cholangiocarcinoma 8 % What will happen afterwards?

22 patients with recurrent PSC 7 received 2 nd transplant 15 received medical care 5 alive14 alive2 dead1 dead 2 relisted What will happen afterwards? About % get recurrent PSC after transplant, but most of these do well.

1) Will I need it? 2) When will I need it? 3) How will it happen? 4) What happens afterwards? Questions about transplant

About ½ of our patients are transplanted 10 years after diagnosis. - - that means ½ are not transplanted Will I need it?

5.My doctor can accurately predict the time when I will need the transplant. Myth

5.Predicting the time of transplant is difficult for individual patients, but there are clues. Reality

Very difficult (impossible) to predict long-term outcomes for single patient. Until When will I need it?

“I’m not sick” weight loss admissions “I’m not that sick” jaundice, more weight loss Itching, ERCP(s) fatigue ETC. “OK, I need a transplant” THE WALL Once your’re jaundice (yellow) and stay jaundice you need to move towards transplant.

1) deceased-donor transplant (full-size liver from a dead person) 2) living-donor transplant (1/2 liver from living donor) 3) off-shore transplant (China) How will it happen?

deceased-donor living donor organ size+++ + timing++++ How will it happen? “Is it better to wait indefinitely on a whole liver or take ½ a liver with ideal timing?”

The preferred route is a whole liver for patients with life-threatening problems from PSC, if you can get one. How will it happen?

6.The MELD at transplant is same around the country. Myth

6.While MELD scores are the same wherever calculated the MELD at transplant varies widely around the country. Reality

Regional sharing

Liver redistricting – new proposal “if some is good, more is better” wider regional sharing in the US fulfills “Final Rule” – access to donors not limited by geographys normalizes access/waitlist mortality supported by: NYC, BOS, SFO, LAX

Liver redistricting – new proposal

Liver redistricting - concerns long-travel times (logistics/cost) penalizes good DSA’s, rewards laggards effects of share-35 not fully assessed worsen outcomes not supported by: organ-rich, low-MELD regions: MO, KS, SC, TN, TX

Liver redistricting - proposal 110/12,000 = 0.9 % lives saved per year 58 DSA’s in US x 2 livers per year = 116 lives saved

PSC – cholangitis and risk of death 171 PSC patients listed pre-listing 38.6% (66/171) cholangitis post-listing 28.0% (44/157) cholangitis removed death/too sick –14.6 % with cholangitis –20.2% without cholangitis (p = 0.34) Goldberg et al, Liver Transpl 2013

PSC – cholangitis and risk of death multivariable model cholangitis significantly decreased risk of removal for death/too sick HR=0.67 p<0.001)